FDA panel to focus on safety of Novartis gene therapy drug – Reuters
Reuters |
FDA panel to focus on safety of Novartis gene therapy drug
Reuters The drugs use a new technology known as CAR-T, or chimeric antigen receptor T–cell therapy, which harnesses the body's own immune cells to recognize and attack malignant cells. If approved they are expected to cost up to $500,000 and generate billions … |
